This study has three primary objectives to address the public health challenges of the Mpox outbreak in Guinea, West Africa. Objective 1 (MOVIE-West Africa) focuses on understanding the kinetics of Monkeypox virus (MPXV) elimination from the human body in Mpox cases. Objective 2 (TRACE-West Africa) aims to determine the MPXV transmission dynamics between Mpox cases and their contacts. Objective 3 (VE-West Africa) examines the vaccine effectiveness of the MVA-BN vaccine in protection against MPXV infection and Mpox disease.
MOVIE-West Africa
Individuals of any sex and age.
Confirmed Mpox cases who tested positive for MPXV by PCR.
Symptom onset within the 10 days prior to the baseline assessment.
Cases of severe Mpox requiring hospitalization.
Individuals with a confirmed alternative diagnosis explaining their illness.
The exclusion criteria for Mpox cases in VE-West Africa are as follows.
Cases of severe Mpox requiring hospitalization.
London School of Hygiene and Tropical Medicine
Lead sponsor
University of Glasgow
Collaborator
Centre National de Formation et de Recherche en Sante Rurale
Collaborator
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Collaborator
Agence Nationale de Sécurité Sanitaire de Guinée (ANSS)
Collaborator
Institut National de la Santé Publique de Guinée (INSP)
Collaborator